Posts by tag
early breast cancer
2 posts
Adding a CDK4/6 inhibitor to endocrine therapy improves outcomes in HR+ HER2– early-stage breast cancer
Adding the CDK4/6 inhibitor ribociclib to standard-of-care adjuvant endocrine therapy for treatment of hormone receptor-positive HER2-negative early-stage breast cancer reduced risk of recurrence by 25%. The phase III NATALEE study, abstract LBA500, presented at the ASCO 2023 Annual Meeting, held…
Hansjörg Senn of St Gallen: A practice-changing career
The speed of progress in breast cancer – not just survival, but also quality of life and survivorship – has been the envy of the wider cancer community for many decades. The factors contributing to this relative success are many…